hsa-miR-331-3p

ncRNA information

ncRNA name

hsa-miR-331-3p

Specific or universal ncRNAs

Specific ncRNAs

Class

MicroRNA

Biomarker

None

Biomarker application

Upstream regulatory factors

Not available

Downstream target

ST7L

Cancer information

Cancer name

Pancreatic Cancer

Cancer site

qRT-PCR,Western blot

Treatment information

Treatment type

Chemotherapy

Drug

Gemcitabine

Impact of wild-type ncRNA on chemotherapy resistance

Up

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

our data demonstrate that miR-331-3p contributes to drug resistance by activating Wnt/Ī²-catenin signaling via ST7L in pancreatic cancer cells

Tissue resource

patients with prostate cancer who had received chemotherapy and had not received chemotherapy plasma samples

human prostate cancer cell lines PANC1

human prostate cancer cell lines MIAPaCa2

prostate cancer drug-resistant cell lines PANC1/Gem

prostate cancer drug-resistant cell lines MIAPaCa2/Gem

Experiment

None


Institute

the Tongren Hospital of Wuhan University and Renmin Hospital of Wuhan University

Cell Bank of Type Culture Collection of Chinese Academy of Sciences

the Central Laboratory of Renmin Hospital of Wuhan University

Country

China

China

China

Continent

Asia

Asia

Asia